Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!

Pachandl-Cheers for your summary of the IC article much appreciated.
My mood since Friday has perked up a bit especially since my beloved Reds
are still in the hunt for the Premiership Title after beating Man City today
Rooney! Rooney! Rooney!

MIDAS-I wish you could have expanded on your bullish comments. Where did
you hear the above rumours of other predators being interested in bidding
for OXB. I bought 'The Times', FT and Sunday 'Times'this weekend but saw no
articles about other predators. I wonder if there were articles in other
newspapers?

MIDAS-I hope the rumours you heard or read are correct but more details would
be appreciated.

I'm anticipating more dips in the sp between Mon-Tuesdays and then more speculators to start investing big money for the rest of the week in anticipation of the Trovax and preliminary results. Should be another exciting week.

I agree with what is being said, as a holder this seems to be a time when one needs to be "IN" even though the product won't reach the market for some years time....we don't know if a deal will happen before the fat lady stops singing (as it were). This being the case each and every rumour will trigger extra buying and it's probably better to have bought on a Low (ie recently wasn't spectatularly high)....rather than attempt to play the stock (ie Patience pays).
Only in the case of those sad Day Traders will it be worth watching and then it may be that rises can be caught several times, but it could be a dangerous assumption so I'm "in and holding" unless the price soars for some silly reason....but will we know for sure?

I agree with you. I think a good long term hold.

Duplicate post from charts thread for anyone interested in week-end.DYOR.
Share price fell from 45p to 25p much like VOG did! Placing completed last month as happened with VOG. Keep a watchful eye on OXB.News is expected soon and buyers returned today after retrace.Needs to hold support at 30p and breakout occurs above 32.5p. Personally expecting shorter and swifter rise back to 45p target price.Short term moves suggest 34p-36p.Plenty more news expected in 2006.Chart has resumed rising trend and high volumes by close today.

Let the trend be your friend.Up 33p-33.5p.

HDB - 9 Jan'06 - 10:39 - 359 of 363

In relation to OXB and the TA there is another interesting fact that has not come to the surface on these threads. OXB has a market cap of 164M and the average cost for Big Pharma to get a drug into the market is $500M and rising. Added to this many big Pahrmas are being less productive with their research and have pipelines that are showing gaps in 2007 and beyond. OXB has a number of products that are entering phase 3 trials but if any of these are close to megabrand status ($1B sales per year) then this would make the current market cap of 165(of which 21% is cash) seem rediculously cheap. While there are still a lot of hurdles to cross between getting a product from Phase II trials to megabrand status I can't help feeling that the balance between risk and reward is starting to swing in OXB's favour and the market conditions are right for Big Pharmas to want to invest in other sources of R&D.

http://search.ft.com/search/totalSearch_Form.html?vsc_appId=ts&symb=&ftsite=FTCOM&searchtype=equity&vsc_query=oxford+biomedica&searchOption=news&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html

Here comes the tree shake.If you can pick 'em up cheaper just what the doctor ordered.

Momentum buying should take oxb much higher this week being bought on TA ma chart breakout and with placing complete likely to return to 45p/46p.

Up 6.35% 33.25p-33.75p.

I had a look at oxford biomedical today. It's got a great chart but the fundamentals seem a bit dodgy. I know this isn't too important in this type of share. (for example, the doubling in vog recently). I might be wrong but from my understanding, it's got no P.E. and it's loss making.

This is what's leaving me uneasy with it at the moment.

Its a Biotech in the research and dev stage so it will be loss making, the investment potential is all in the future possibilities with profits of 100s of millions if only one of their products reaches market. One of the best Biotechs you can invest in though with enormous potential and the institutions are coming round to realising that!

Keep an eye on Oxford Biomedica-oxb. On the rise (UPS) and potential break-out back to 46p.Late ground breaking announcement late today and more news expected.Buses arriving in threes comes to mind.

http://www.biotech-intelligence.com/html/html/9904d1fab80d627f5da59efaf1a2d3d4.html

http://www.advfn.com/p.php?pid=nmona&cb=1137613512&article=13842043&symbol=L%5EOXB

http://www.advfn.com/p.php?pid=nmona&cb=1137613512&article=13842549&symbol=L%5EOXB

Link to most recent charts by Fingers xxxd
http://www.advfn.com/cmn/fbb/thread.php3?id=5456944&from=3940

Wed 18 OXB 32.75p lex1000 Dropped from previous highs of 46p,placing @ 25p completed, institutional placing oversubscribed 2.5 times.Chart in rising trend.On the rise above major resistance at 32.5p and ground breaking news announced within last half hour of close.Back to 46p.

That would be nice :)

from Reuters:

http://investing.reuters.co.uk/investing/financeArticle.aspx?type=allBreakingNews&storyID=2006-01-18T162931Z_01_L18626054_RTRIDST_0_HEALTH-OXFORDBIO-VIRAGEN.XML


Biotech chicken advance boosts Oxford Bio, Viragen
Wed Jan 18, 2006 4:29 PM GMT
Printer Friendly | Email Article | RSS


LONDON, Jan 18 (Reuters) - Shares in Britain's Oxford BioMedica Plc (OXB.L: Quote, Profile, Research) and U.S.-based Viragen Inc (VRA.A: Quote, Profile, Research) gained on Wednesday following progress in a project to produce drugs in genetically modified hens' eggs.

BioMedica said a collaboration with Viragen and the Roslin Institute had, for the first time, produced significant quantities of interferon beta-1a in the whites of eggs laid by genetically modified chickens.

Interferon beta-1a is a key component of the human immune system and the active ingredient in several multiple sclerosis drugs.

Several biotech groups are working on ways to produce various complex protein drugs in milk, eggs or farm crops, as a cheap alternative to making them from cell cultures in stainless steel vats.

BioMedica shares gained 4.7 percent to 33-1/2 pence, while Viragen jumped 31 percent to 71 cents.

.

strong open.


Pharma sector to do well in 2006... FT
- OXB big Lentivector breakthrough- yesterday

- FT '2006 may well be a year for Growth stocks.. rally of several months in growth stocks likely'. Bios are 'Growth/defensive'.
.

tick up.2v2

OXB has not broken out...............yet.UBS declared no notifiable interest a few days ago and back above 3% today. Chart and rising trend intact.Support holding @{ 30p and waiting for hold and break above 33p. News can come at any time.

badday - 26 Jan'06 - 21:18 - 29262 of 29263


Scottie, not exactly the queens english, but i suspect that qpr will be very right!
There's an enormous amount of news building up, which could come at any time.

Dept of Health Funding
SPA approval from FDA for Trovax phase111 trials
Trovax deal
Approval for Prosavin trials
Metxia results
Additional funding for Monudin
And of course the usual surprises from Retinostat and Lentivectors.
With Results and AGM etc thrown into the pot the coming months should certainly not be lacking in interest.


8 Mar 2006 Center for Business Intelligence Gene Therapy Research Symposium
Cambridge, Massachusetts, USA

8-10 Mar 2006 BioSquare 2006
Geneva, Switzerland

28-30 Mar 2006 British Society for Gene Therapy (BSGT) Meeting
London, UK

29-30 Mar 2006 Ocular Anti-angiogenesis Meeting
London, UK

1-8 Apr 2006 58th Annual American Academy of Neurology Meeting
San Diego, California, USA

9-12 Apr 2006 BIO 2006 Annual International Convention
Chicago, Illinois, USA

30 Apr-4 May 2006 Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting
Fort Lauderdale, Florida, USA



qpr67 - 26 Jan'06 - 21:25 - 29263 of 29263


badday

One more to note :

5-7 Feb 2006 4th Annual BioPartnering North America (BPN) Conference
Vancouver, Canada

badday - 27 Jan'06 - 07:30 - 29270 of 29278


Another bio bull

The highly regarded Findlay Park US Smaller Companies fund has bought almost 10% of International Biotechnology Trust in anticipation of an upturn in the biotech sector.

James Findlay, who is widely regarded as one the best US smallcap pickers operating out of London, told Citywire: 'We have a feeling that the biotechnology sector after several years will start to do a bit better.' He added, 'Our weakness is that we don't know much about individual technology or biotechnology companies.'

oxb back tested 30p,support held firm.On the rise again.